SequelSEC

TENAX THERAPEUTICS, INC. TENX

Pharmaceutical Preparations · CIK 0000034956 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$56.38M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

TENAX THERAPEUTICS, INC. (TENX) reported revenue of $0 and net income of -$52.60M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from TENAX THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TENAX THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312016-12-312015-04-302014-04-30
Revenue$0$0$0$49.29K$158.93K
Cost of revenueUnavailableUnavailable$0UnavailableUnavailable
Gross profitUnavailableUnavailable$0UnavailableUnavailable
Operating income-$56.38M-$19.49M-$52.65M-$14.82M-$16.61M
Net income-$52.60M-$17.60M-$43.92M-$14.08M-$19.54M
Research & development$32.67M$12.71M$13.14M$6.66M$3.00M
Weighted-average diluted sharesshares 39.22Mshares 15.27MUnavailableshares 28.08Mshares 9.36M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0-$7.96M$0$0
Diluted EPS$-1.34$-1.15UnavailableUnavailable$-2.71
Selling, general & administrativeUnavailableUnavailable$6.25M$7.17M$13.77M
General & administrative$23.71M$6.78MUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

TENAX THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312016-12-312015-04-302014-04-30
Cash & equivalents$97.60M$94.90M$10.00M$7.93M$58.32M
Total assets$104.23M$96.69M$23.34M$82.91M$93.43M
Current assets$104.23M$96.69M$13.63M$17.51M$58.97M
Total liabilities$7.16M$4.69M$6.20M$12.48M$10.54M
Current liabilities$7.16M$4.69M$6.20M$4.52M$2.57M
Total equity incl. NCI$97.07M$91.99M$17.14M$70.43M$82.86M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable$0
Accounts receivableUnavailableUnavailable$72.60K$76.48K$36.36K
GoodwillUnavailableUnavailable$0$11.27M$11.27M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.04M$3.16M$727.60K$1.18M$411.14K

Cash flow

TENAX THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312016-12-312015-04-302014-04-30
Operating cash flow-$35.80M-$14.81M-$15.87M-$9.75M-$9.26M
Capital expendituresUnavailableUnavailable$2.88K$4.23K$9.80K
Investing cash flowUnavailable$0$22.21M-$40.93M-$147.04K
Financing cash flow$38.51M$99.87M$0$280.59K$66.95M
Net change in cashUnavailableUnavailable$6.34M-$50.39M$57.54M
Stock-based compensation$19.16M$1.12M$1.06K$117.30K$651.46K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$0$18.95K$148.14K$150.49K

Derived

TENAX THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312016-12-312015-04-302014-04-30
Free cash flowUnavailableUnavailable-$15.87M-$9.75M-$9.27M
Gross marginUnavailableUnavailableUnavailable0.0%-65.5%
Operating marginUnavailableUnavailableUnavailable-30062.8%-10452.1%
FCF marginUnavailableUnavailableUnavailable-19788.6%-5833.8%
SBC / revenueUnavailableUnavailableUnavailable238.0%409.9%
Current ratio14.56x20.60x2.20x3.88x22.93x
Revenue YoY growthUnavailableUnavailableUnavailable-69.0%Unavailable
Net marginUnavailableUnavailableUnavailable-28571.6%-12296.2%
R&D / revenueUnavailableUnavailableUnavailable13513.8%1885.6%
CapEx / revenueUnavailableUnavailableUnavailable8.6%6.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TENX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2015-04-30

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2014-04-30

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.